Madrigal Pharma (NASDAQ: MDGL) reported Q2 EPS of ($1.99), $0.76 better than the analyst estimate of ($2.75). Revenue for the quarter came in at $364.3 million versus the consensus estimate of $349.15 million.

For earnings history and earnings-related data on Madrigal Pharma (MDGL) click here.